Dieser Anti-APOE Antikörper ist ein Maus Monoklonal Antikörper zur Detektion von APOE in WB, IHC, ELISA und FACS. Geeignet für Human. Dieses Primary Antibody wurde in 1 Publikation zitiert.
Western Bloting: 1/500 - 1/2000. Immunohistochemistry: 1/200 - 1/1000. Flow cytometry: 1/200 - 1/400. ELISA: Propose dilution 1/10000. Not yet tested in other applications. Determining optimal working dilutions by titration test.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C
Zintzaras, Kitsios, Triposkiadis, Lau, Raman: "APOE gene polymorphisms and response to statin therapy." in: The pharmacogenomics journal, Vol. 9, Issue 4, pp. 248-57, (2009) (PubMed).
Target
APOE
(Apolipoprotein E (APOE))
Andere Bezeichnung
ApoE
Hintergrund
Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptormediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. Tissue specificity: Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle. Synonyms: AD2, LPG, LDLCQ5, MGC1571